X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1294) 1294
Publication (89) 89
Book / eBook (11) 11
Book Review (10) 10
Book Chapter (7) 7
Magazine Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (776) 776
animals (723) 723
male (609) 609
index medicus (575) 575
parkinson's disease (573) 573
antiparkinson agents - pharmacology (529) 529
parkinson disease - drug therapy (495) 495
antiparkinson agents - therapeutic use (485) 485
neurosciences (412) 412
rats (373) 373
pharmacology & pharmacy (341) 341
female (338) 338
parkinsons-disease (245) 245
antiparkinson agents - chemistry (238) 238
levodopa - therapeutic use (223) 223
antiparkinson agents - administration & dosage (219) 219
levodopa (217) 217
biochemistry & molecular biology (206) 206
middle aged (206) 206
mice (204) 204
antiparkinson agents - adverse effects (198) 198
dopamine (191) 191
aged (180) 180
antiparkinson agents - pharmacokinetics (178) 178
l-dopa (169) 169
disease models, animal (146) 146
clinical neurology (144) 144
parkinson disease - metabolism (143) 143
rats, sprague-dawley (140) 140
chemistry, medicinal (132) 132
levodopa - adverse effects (129) 129
parkinson disease - physiopathology (127) 127
levodopa - pharmacology (124) 124
adult (123) 123
dopamine - metabolism (122) 122
dose-response relationship, drug (113) 113
parkinsonian disorders - drug therapy (113) 113
levodopa - administration & dosage (112) 112
oxidative stress (110) 110
analysis (103) 103
antiparkinson agents - chemical synthesis (101) 101
dopa (100) 100
motor activity - drug effects (100) 100
neurology (97) 97
brain (91) 91
rats, wistar (90) 90
neurons (85) 85
parkinsons disease (83) 83
levodopa - pharmacokinetics (82) 82
neuroprotective agents - pharmacology (79) 79
brain - metabolism (78) 78
neurodegenerative diseases (78) 78
mice, inbred c57bl (77) 77
antiparkinson agents - metabolism (76) 76
movement disorders (76) 76
pharmacokinetics (76) 76
motor fluctuations (75) 75
substantia-nigra (75) 75
behavior, animal - drug effects (74) 74
disease (74) 74
time factors (73) 73
corpus striatum - metabolism (72) 72
structure-activity relationship (72) 72
neuroprotection (71) 71
basal ganglia (68) 68
brain - drug effects (66) 66
corpus striatum - drug effects (66) 66
neurons - drug effects (66) 66
antiparkinson agents - blood (65) 65
drug combinations (65) 65
antiparkinsonian agents (64) 64
parkinson’s disease (63) 63
treatment outcome (63) 63
alpha-synuclein (62) 62
drug therapy (62) 62
drugs (62) 62
parkinson disease (62) 62
double-blind (61) 61
dyskinesia (61) 61
antiparkinson agents (59) 59
research (59) 59
chemistry, analytical (58) 58
parkinson disease - pathology (58) 58
striatum (58) 58
in-vitro (56) 56
oxidopamine (56) 56
therapy (56) 56
administration, oral (54) 54
alzheimers-disease (54) 54
molecular structure (54) 54
neurodegeneration (54) 54
psychiatry (54) 54
chromatography, high pressure liquid (53) 53
antiparkinson agents - toxicity (52) 52
chemistry, multidisciplinary (52) 52
drug therapy, combination (51) 51
in-vivo (51) 51
neurons - metabolism (51) 51
in vitro techniques (50) 50
6-hydroxydopamine (48) 48
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1289) 1289
French (4) 4
German (4) 4
Russian (3) 3
Chinese (2) 2
Italian (2) 2
Czech (1) 1
Japanese (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles
Journal Article
Progress in Neurobiology, ISSN 0301-0082, 2010, Volume 92, Issue 3, pp. 330 - 344
Journal Article
Journal Article
Nutrition, ISSN 0899-9007, 2012, Volume 28, Issue 11, pp. 1081 - 1088
Abstract Ginkgo Biloba extract 761 (EGb 761) is a patented and well-defined mixture of active compounds extracted from Ginkgo biloba leaves. This extract... 
Gastroenterology and Hepatology | Neuroprotection | Dopamine | Natural extract | Antioxidant | Recovery | OXIDATIVE STRESS | SUBSTANTIA-NIGRA NEURONS | LIPID-PEROXIDATION | STANDARDIZED EXTRACT | EGB761 PROTECTS | DOPAMINERGIC NEUROTOXICITY | NUTRITION & DIETETICS | SUPEROXIDE-DISMUTASE ACTIVITY | MONOAMINE-OXIDASE ACTIVITY | IN-VIVO | MOUSE CORPUS STRIATUM | Neuroprotective Agents - therapeutic use | Plant Extracts - chemistry | Antioxidants - chemistry | Oxidative Stress | Mesencephalon - metabolism | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Dietary Supplements - analysis | Antiparkinson Agents - therapeutic use | Dopaminergic Neurons - metabolism | Antiparkinson Agents - chemistry | Parkinson Disease - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Phytotherapy | Parkinson Disease - diet therapy | Disease Models, Animal | Neuroprotective Agents - chemistry | Antiparkinson Agents - adverse effects | Antioxidants - therapeutic use | Parkinson Disease - prevention & control | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antioxidants - adverse effects | Plant Extracts - therapeutic use | Apoptosis | Plant Extracts - adverse effects | Drugs | Antioxidants | Parkinson's disease | Neurons | Analysis | Medicine, Botanic | Medicine, Herbal | Health aspects | Isoflavones | Studies | Oxidative stress | Chinese medicine | Neurotoxicity | Free radicals | Acids | Neurodegeneration | Rodents | Dementia | Index Medicus
Journal Article
ACS Chemical Neuroscience, ISSN 1948-7193, 04/2017, Volume 8, Issue 4, pp. 723 - 730
Journal Article
Journal Article
Journal Article
BMC Neuroscience, ISSN 1471-2202, 08/2016, Volume 17, Issue 1, p. 58
Background: Parkinson disease (PD) is a movement disorder affecting 1 % of people over the age of 60. The etiology of the disease is unknown; however,... 
Parkinson disease | Oxidative stress | Nerolidol | Neurodegeneration | Rotenone | MICROGLIAL ACTIVATION | ESSENTIAL OIL | ALPHA-SYNUCLEIN | DOPAMINERGIC-NEURONS | MODEL | SUBSTANTIA-NIGRA | NEUROSCIENCES | ANTIOXIDANT | CHEMICAL-COMPOSITION | ANTIINFLAMMATORY ACTIVITIES | PARKINSONS-DISEASE | Antiparkinson Agents - pharmacology | Antioxidants - chemistry | Rats, Wistar | Dopaminergic Neurons - pathology | Neuroglia - pathology | Oxidative Stress - physiology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Neuroimmunomodulation - physiology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Neuroglia - drug effects | Brain - metabolism | Parkinsonian Disorders - metabolism | Neuroprotective Agents - pharmacology | Parkinsonian Disorders - drug therapy | Dopaminergic Neurons - metabolism | Lipid Peroxidation - drug effects | Antiparkinson Agents - chemistry | Dopaminergic Neurons - drug effects | Molecular Structure | Neuroprotective Agents - chemistry | Sesquiterpenes - chemistry | Injections, Intraperitoneal | Antioxidants - pharmacology | Lipid Peroxidation - physiology | Brain - drug effects | Animals | Parkinsonian Disorders - pathology | Brain - pathology | Neuroglia - metabolism | Oxidative Stress - drug effects | Sesquiterpenes - pharmacology | Neuroimmunomodulation - drug effects | Parkinson's disease | Neurons | Physiological aspects | Research | Drug therapy | Health aspects
Journal Article
Journal Article